Expert Insights

Conference Coverage

Front-Line Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab for HR-Positive, HER2-Positive Metastatic Breast Cancer

12/19/2023

Featuring Amy Tiersten, MD

Amy Tiersten, MD, Mount Sinai, discussed results from the phase 1/2 ASPIRE study investigating combination anastrozole, palbociclib, trastuzumab, and pertuzumab for previously untreated patients with HR-positive, HER2-positive metastatic...

Amy Tiersten, MD, Mount Sinai,...

12/19/2023

Oncology

Daniel Wolff, MD, University Hospital Regensburg

Conference Coverage

AGAVE-201 Trial Finds Axatilimab Yields Durable Responses for R/R Chronic GVHD Treatment

12/18/2023

Featuring Daniel Wolff, MD

At the 2023 ASH Annual Meeting in San Diego, Daniel Wolff, MD, presented phase 2 data on axatilimab treatment of patients with heavily pretreated R/R chronic GVHD, which yielded robust clinical activity and durable responses within 3 dose...

At the 2023 ASH Annual Meeting...

12/18/2023

Oncology

Conference Coverage

Long-Term Survival Rates and Discontinuation of Venetoclax/Azacitidine for Responding Patients With AML

12/15/2023

Featuring Sylvain Garciaz, MD

At the 65th ASH Annual Meeting, Sylvain Garciaz, MD, shared insights on the potential benefit of stopping venetoclax and/or azacytidine treatment for responding patients with acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

12/15/2023

Oncology

Conference Coverage

Augment-101 Study Shows Revumenib Yields High Overall Response Rate for Patients With Heavily Pretreated KMT2Ar Acute Leukemia

12/13/2023

Featuring Ibrahim Aldoss, MD

At the 65th ASH Annual Meeting, Ibrahim Aldoss, MD, shared phase 2 results on the value of revumenib monotherapy among patients with heavily pretreated, relapsed/refractory KMT2Ar acute leukemia.

At the 65th ASH Annual Meeting,...

12/13/2023

Oncology

Conference Coverage

Promising Efficacy of Frontline Nivolumab in Combination With R-CHOP for Patients With High-Risk DLBCL

12/12/2023

Featuring Oluwatobi Odetola, MD

Featuring Oluwatobi Odetola, MD ...

During the 2023 ASH Annual Meeting in San Diego, Oluwatobi Odetola, MD, shared data from a phase 1b study that evaluated the safety and efficacy of nivolumab in combination with R-CHOP in high-risk DLBCL.

During the 2023 ASH Annual...

12/12/2023

Oncology

Conference Coverage

Evaluating Effects of Racial Disparities on the Treatment of Patients With Chronic Lymphocytic Leukemia

12/12/2023

Fetauring Ira L Zackon, MD

At the 65th ASH Annual Meeting, Ira L Zackon, MD, presented real-world data from a large community oncology setting on the racial disparities observed in chronic lymphocytic leukemia treatment.

At the 65th ASH Annual Meeting,...

12/12/2023

Oncology

Conference Coverage

Naturally Selected CD7 CAR-T Cell Therapy Shows Promise for CD7-Positive AML Treatment

12/12/2023

Featuring Peihua Lu, MD

At the 65th ASH Annual Meeting, Peihua Lu, MD, highlights the promising efficacy and safety outcomes of NS7CAR T-cell therapy as a potential bridging therapy for patients with CD7-positive acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

12/12/2023

Oncology

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Considerations for Endocrine Therapy for Patients With ER-Positive Early Breast Cancer

12/12/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 4 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for endocrine therapy for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 4 of...

12/12/2023

Oncology

Videos

Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer

12/12/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 3 of...

12/12/2023

Oncology

Vivek Subbiah, MD, Sarah Cannon Research Institute

Videos

Management of Adverse Events Associated With FGFR Inhibitors

12/12/2023

Featuring Vivek Subbiah, MD

Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.

Vivek Subbiah, MD, discusses the...

12/12/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology